Elsevier and Roche Collaborate To Integrate Proprietary Chemistry Data In Reaxys®
Roche researchers expected to benefit from increased discoverability of in-house chemistry content, integrated and unified with externally validated content, directly retrievable in Reaxys
Frankfurt, Germany, October 1, 2012 – Elsevier today announced the integration of Roche propriety reaction information within Reaxys, which will run on Roche’s infrastructure and inside the Roche firewall to provide high performance and security. Roche chemistry information will be securely searchable and discoverable by Roche scientists through the Reaxys user interface. The incorporation and discoverability of Roche proprietary information in Reaxys is anticipated to significantly improve Roche scientists’ productivity.
With this development Roche researchers will be able to launch a single search in Reaxys across integrated internal data and experimental data published in journals and patents, with results unified and organised in a context directly relevant to the researcher workflow. The announcement comes after many months of collaboration between teams from Roche and Reaxys.
“We have been seeking to improve the discoverability of our in-house proprietary content, while at the same time avoiding investing in and maintaining an entirely new internally or externally developed system,” explained Sven-Olaf Vogt, Global Head Scientific Information Management at Roche. “Working with the Reaxys team was a logical choice given the widespread adoption of Reaxys at Roche and the knowledge of the Reaxys team in chemistry content.”
Mark van Mierle, Managing Director of Elsevier’s Pharma and Biotech Group, added, “Our collaboration with Roche shows how we can work together with customers to serve scientist needs. Researchers want seamless, unified data streams, delivered through highly intuitive workflow tools. Our work with Roche responds directly to those needs and enables researchers to innovate more effectively by accessing data they need, through a world-leading interface.”
# # #
Reaxys® is a workflow solution for research chemists. Offering a wealth of experimentally validated information, Reaxys® combines reaction and substance data in organic, organometallic, inorganic and physical chemistry with synthesis planning. Researchers can get the information they need in a single overview, from source publications carefully selected for their importance and relevance to research chemists. Elsevier continues to engage with the chemistry community to ensure that Reaxys® continues to reflect how chemists think and work. https://www.reaxys.com/info/
Reaxys ® and the Reaxys trademark are owned and protected by Reed Elsevier Properties SA and used under license.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby’s Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).Media contact
Vice President, Global Corporate Relations
+ 1 215 239 3508